Teacher Retirement System of Texas Increases Stock Position in Zoetis Inc. $ZTS

Teacher Retirement System of Texas grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 20.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 179,887 shares of the company’s stock after purchasing an additional 30,808 shares during the quarter. Teacher Retirement System of Texas’ holdings in Zoetis were worth $26,321,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Probity Advisors Inc. increased its position in Zoetis by 9.9% during the third quarter. Probity Advisors Inc. now owns 1,421 shares of the company’s stock worth $208,000 after buying an additional 128 shares during the period. MOKAN Wealth Management Inc. grew its position in shares of Zoetis by 7.9% during the third quarter. MOKAN Wealth Management Inc. now owns 8,557 shares of the company’s stock worth $1,252,000 after acquiring an additional 624 shares during the last quarter. iA Global Asset Management Inc. grew its position in shares of Zoetis by 38.7% during the third quarter. iA Global Asset Management Inc. now owns 34,480 shares of the company’s stock worth $5,045,000 after acquiring an additional 9,628 shares during the last quarter. Naples Global Advisors LLC increased its holdings in shares of Zoetis by 72.7% in the 3rd quarter. Naples Global Advisors LLC now owns 2,515 shares of the company’s stock valued at $368,000 after acquiring an additional 1,059 shares during the period. Finally, Strs Ohio raised its position in Zoetis by 7.0% in the 3rd quarter. Strs Ohio now owns 157,197 shares of the company’s stock valued at $23,001,000 after purchasing an additional 10,298 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.3%

NYSE ZTS opened at $124.04 on Friday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $54.66 billion, a P/E ratio of 20.88, a P/E/G ratio of 2.16 and a beta of 0.97. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.40. The firm has a 50-day moving average price of $123.58 and a 200 day moving average price of $138.43.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a $0.53 dividend. The ex-dividend date is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ZTS. Bank of America downgraded shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price objective on the stock. in a research report on Monday, December 15th. UBS Group decreased their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings upgraded Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 13th. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, Stifel Nicolaus lowered their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Five equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.